精华制药(002349) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 reached ¥360,864,815.60, representing an increase of 11.08% compared to the same period last year[5] - Net profit attributable to shareholders was ¥45,728,260.43, a significant increase of 58.78% year-on-year[5] - The basic earnings per share for the period was ¥0.0551, reflecting a growth of 55.65% compared to the previous year[5] - Total operating revenue for the current period reached ¥1,092,285,389.95, an increase of 4.5% compared to ¥1,045,172,312.93 in the previous period[18] - Net profit for the current period was ¥209,552,451.74, representing a 10% increase from ¥190,509,038.34 in the previous period[19] - Earnings per share (EPS) for the current period was ¥0.2148, compared to ¥0.2017 in the previous period, indicating a growth of 15.4%[20] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥3,487,847,864.98, marking a 5.64% increase from the end of the previous year[5] - The company’s financial assets increased by 339.90% to ¥462,589,373.70 due to increased investment in financial products[8] - Total current assets increased from 1,844,302,643.64 CNY to 1,954,574,731.10 CNY, an increase of about 6%[15] - The total liabilities increased to ¥393,504,467.73 from ¥344,656,275.77, representing a growth of 14.2%[17] - Total equity rose to ¥3,094,343,397.25 from ¥2,957,123,501.37, indicating an increase of 4.6%[17] Cash Flow - The company reported a net cash flow from operating activities of ¥224,559,700.16, which is a 22.81% increase year-to-date[5] - Cash inflow from operating activities totaled ¥1,125,494,646.11, an increase from ¥1,054,807,090.96 in the previous period, marking a growth of 6.7%[21] - The net cash flow from operating activities was $224,559,700.16, an increase of 23% compared to $182,850,167.68 in the previous period[22] - Cash inflow from investment activities totaled $891,894,302.17, up from $710,856,913.71, marking a 25.5% increase[22] - The net cash flow from investment activities was -$476,496,188.50, a significant decrease from $303,073,347.40 in the prior period[22] Shareholder Information - Total number of common shareholders at the end of the reporting period is 88,812[11] - The largest shareholder, Nantong Industrial Holdings Group Co., Ltd., holds 33.75% of shares, totaling 279,994,660 shares[11] - The company has no preferred shareholders as indicated in the report[13] Expenses - Total operating costs amounted to ¥853,284,673.64, up from ¥825,883,624.70, reflecting a year-over-year increase of 3.3%[18] - Research and development expenses were ¥43,536,583.86, slightly down from ¥47,149,976.95, showing a decrease of 7%[19] - Sales expenses increased to ¥203,123,914.20 from ¥183,281,978.47, reflecting an increase of 10.8%[19] Investment Activities - The company’s investment payments surged by 224.66% to ¥1,233,700,000.00, reflecting a significant increase in financial product purchases[9] - The company’s cash flow from other investment activities decreased by 77% to ¥10,618,402.78, primarily due to reduced cash recovery from related activities[9] - The company received $878,000,000.00 from the recovery of investments, an increase from $656,137,829.10[22] - The company paid $121,051,082.31 in cash related to other investment activities, significantly higher than $1,117,714.05 in the previous period[22]